News and Trends 30 May 2023 Molecular Partners presenting positive solid tumor data Molecular Partners AG will present additional positive data from the ongoing phase 1 study of MP0317, a CD40 agonist designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), at the 2023 ASCO (American Society of Clinical Oncology) annual meeting, June 2 to 6 in Chicago, U.S. The […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2023 UK invests £650M in life sciences A £650 million ($804 million) war-chest to boost the U.K.’s life sciences sector has been announced. The ‘Life Sci for Growth’ package brings together 10 different policies including £121 million ($150 million) to improve commercial clinical trials to bring new medicines to patients faster, up to £48 million ($59.4 million) of new money for scientific […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 May 2023 Could new Lyme disease tests help to prevent chronic infection? Lyme disease is the most common vector-borne disease in the U.S. – a new CDC estimate suggests that approximately 476,000 Americans are diagnosed with Lyme disease each year – and it is caused by the bacterium Borrelia burgdorferi. It is primarily transmitted to humans through the bite of an infected Ixodes tick; also known as […] May 26, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 26 May 2023Beyond Biotech podcast 47 The companies Daiichi Sankyo and AstraZeneca have worked together for several years. This week’s podcast is sponsored by Daiichi Sankyo and AstraZeneca. On this week’s podcast, we have a conversation with Markus Kosch, the head of Oncology Europe and Canada for Daiichi Sankyo, and Greg Rossi, Senior Vice President, Oncology, Europe and Canada, from AstraZeneca, who are joining […] May 26, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 VarmX raises €30M for blood clotting trial VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has successfully raised an additional €30 million ($32.2 million) in a Series B2 financing round. The round was led by Sound Bioventures while the European Innovation Council (EIC) Fund also joined as a new investor. Existing investors EQT Life […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Novartis buys AVROBIO cystinosis gene therapy program for $87.5M AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for […] May 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Rocket Pharmaceuticals receives FDA designation for pyruvate kinase deficiency gene therapy Rocket Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the company’s investigational lentiviral-based gene therapy for pyruvate kinase deficiency (PKD). PKD is a rare blood disorder characterized by severe anemia and excessive red blood cell breakdown. RMAT designation was granted based […] May 26, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2023 Transgene and BioInvent report positive solid tumor results Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, have announced positive phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent […] May 26, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 Researchers discover genetic variation offers Alzheimer’s disease clues A new study conducted by researchers at the University of Eastern Finland discovered that the APP A673T genetic variant, which protects against Alzheimer’s disease (AD), alters levels of several proteins and peptides linked to amyloid-beta metabolism in human biofluids and cell culture models, including amyloid beta itself. These new data support the idea that even […] May 25, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 smartbax raises €1.2M to create next-generation antibiotics smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million ($1.3 million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million ($2.1 million). The funds will be used to advance smartbax’s small molecule […] May 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2023 Major progress as Swedish scientists get brain tumors to self destruct Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […] May 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email